Poor
Mostly Aligned
Patient Risk:
Low
Summary
Some statements about Tezspire/tezepelumab and its biologic monoclonal antibody nature align with the provided label excerpt (tezepelumab-ekko). However, the response content supplied does not explicitly evaluate those claims, and it also introduces/assesses an acute-relief use scenario that is not present in the user-provided claims list. Because the audit cannot reliably confirm label support for the assessed claim(s) and includes a contradiction assessment not traceable to the provided claims, alignment is poor.
Category Scores
Accurate Statements
Tezspire is tezepelumab (tezepelumab-ekko).
Label excerpt Section 12.1 Mechanism of Action refers to “Tezepelumab-ekko”. The active ingredient line provided in the prompt states “tezepelumab-ekko”.
Tezspire is a biologic monoclonal antibody.
Prompt excerpt under “Active ingredient(s)” states “monoclonal antibody”; label excerpt Section 12.1 describes tezepelumab-ekko as a TSLP blocker binding to human TSLP (consistent with monoclonal antibody description provided in the prompt).
Unsupported Statements
Tezspire's brand name is Tezspire.
The provided label excerpts do not explicitly support/deny this naming statement; it is not directly stated in the supplied excerpts.
Any generic versions of Tezspire would most likely be biosimilars, not traditional small-molecule generics.
No information in the supplied labeling excerpts addresses generics vs biosimilars or traditional small-molecule generics.
The response/evaluation logic correctly identifies a label-backed contraindication-to-use scenario (not for acute relief).
This assessed acute-relief claim is not present in the user-provided claims list. The audit therefore cannot be verified as support for any specific provided claim.
Contradictions
Low
AI Statement
TEZSPIRE can be used to treat acute bronchospasm or status asthmaticus / acute asthma symptoms or acute exacerbations.
Label Reference
SECTION 1: “TEZSPIRE is not indicated for the relief of acute bronchospasm or status asthmaticus.”; SECTION 5.2: “should not be used to treat acute asthma symptoms or acute exacerbations. Do not use TEZSPIRE to treat acute bronchospasm or status asthmaticus.”
Important Omissions
A clear mapping/evaluation from the supplied user claims (five naming/biologic/generic-type statements) to the cited label excerpts. The provided evaluation instead centers on an acute-relief use scenario that is not among the user-provided claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only label-contradicted scenario identified is an acute-relief use restriction (not supported by the label). However, because this scenario is not directly tied to any of the user-provided claims, the practical patient-risk impact from the evaluated content is uncertain; overall risk is assessed as low due to lack of direct, on-label-mismatched instructions in the provided claims list.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
The audit content does not accurately correspond to the user-provided claims list and introduces an acute-relief scenario that is not traceable to those claims.
Suggested Improvement
Evaluate each of the five provided claims explicitly against the supplied prescribing-information excerpts (e.g., cite where “tezepelumab-ekko” and monoclonal antibody are stated, and note that generics/biosimilars guidance is not addressed in the provided label excerpts). Remove or separately handle any contradictions that do not correspond to an actual user claim.